Vascular Remodeling and Prothrombotic Markers in Subjects Affected by Familial Combined Hyperlipidemia and/or Metabolic Syndrome in Primary Prevention for Cardiovascular Disease

REFERENCES

• Cicero A. F., Dormi A., Nascetti S., Panourgia M. P., Grandi E., D'Addato S., Gaddi A. Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: An 8-year follow-up. Diabetic Medicine 2005; 22: 1263–1266
   PubMed Web of Science ®Google Scholar
• Cicero A. F., Manca M., Bove M., Dormi A., Borghi C., Gaddi A. V., for the Brisighella Heart Study Group. Detection of familial combined hyperlipoproteinaemia patients in the Brisighella Heart Study historical cohort: An epidemiological approach. Journal of Inherited Metabolism Disease 2007; 30: 268
   PubMed Web of Science ®Google Scholar
• Derosa G., D'Angelo A., Ciccarelli L., Piccinni M. N., Pricolo F., Salvadeo S., Montagna L., Gravina A., Ferrari I., Galli S., Paniga S., Tinelli C., Cicero A. F. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227–231
   PubMed Web of Science ®Google Scholar
• Derosa G., Cicero A. F., Scalise F., Avanzini M. A., Tinelli C., Piccinni M. N., Peros E., Geroldi D., Fogari E., D'Angelo A. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 2007a; 14: 45–51
   PubMed Web of Science ®Google Scholar
• Derosa G., D'Angelo A., Tinelli C., Devangelio E., Consoli A., Miccoli R., Penno G., Del Prato S., Paniga S., Cicero A. F. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes and Metabolism 2007b; 33: 129–134
   PubMed Web of Science ®Google Scholar
• Dollery C. M., McEwan J. R., Henney A. M. Matrix metalloproteinases and cardiovascular disease. Circulation Research 1995; 77: 863–868
   PubMed Web of Science ®Google Scholar
• El Messal M., Beaudeux J. L., Drissi A., Giral P., Chater R., Bruckert E., Adlouni A., Chapman M. J. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clinica Chimica Acta 2006; 366: 185–189
   PubMed Web of Science ®Google Scholar
• Gaddi A. V., Galetti C., Pauciullo P., Arca M., on behalf of the Committee of experts of the Atherosclerosis and Dysmetabolic Disorders Study Group. Familial combined hyperlipoproteinemia: Experts panel position on diagnostic criteria for clinical practice. Nutrition Metabolism and Cardiovascular Disease 1999; 9: 304–311
   PubMed Web of Science ®Google Scholar
• Grundy S. M., Hansen B., Smith S. C., Cleeman J. I., Kahn R. A., for Conference Participants. Clinical Management of Metabolic Syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004; 109: 551–556
   PubMed Web of Science ®Google Scholar
• Hopkins P. N., Heiss G., Ellison R. C., Province M. A., Pankow J. S., Eckfeldt J. H., Hunt S. C. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108: 519–523
   PubMed Web of Science ®Google Scholar
• Ikeda U., Shimada K. Matrix metalloproteinases and coronary artery diseases. Clinical Cardiology 2003; 26: 55–59
   PubMed Web of Science ®Google Scholar
• Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma level of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. American Heart Journal 2001; 141: 211–217
   PubMed Web of Science ®Google Scholar
• Jude B., Agraou B., McFadden E. P., Susen S., Bauters C., Lepelley P., Vanhaesbroucke C., Devos P., Cosson A., Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation 1994; 50: 1662–1668
   Google Scholar
• Kuzuya M., Iguchi A. Role of matrix metalloproteinases in vascular remodelling. Journal of Atherosclerosis and Thrombosis 2003; 10: 275–282
   PubMedGoogle Scholar
• Lewandowski K. C., Komorowski J., O'Callaghan C. J., Tan B. K., Chen J., Prelevic G. M., Randeva H. S. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006; 91: 1173–1177
   PubMed Web of Science ®Google Scholar
• Nagase H., Woessner J. F. Matrix metalloproteinases. Journal of Biological Chemistry 1999; 274: 21491–21494
   PubMed Web of Science ®Google Scholar
• NCEP A TP, III. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Journal of the American Meidcal Association 2001; 285: 2486–2497
   PubMed Web of Science ®Google Scholar
• Sierevogel M. J., Pasterkamp G., de Kleijn D. P., Strauss B. H. Matrix metalloproteinases: A therapeutic target in cardiovascular disease. Current Pharmacological Design 2003; 9: 1033–1040
   PubMed Web of Science ®Google Scholar
• Vincenti M. P. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase genes. Methods in Molecular and Cellular Biology 2001; 151: 121–148
   Google Scholar